Compare Marathon Petroleum Corp (MPC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs BIO-TECHNE Corp — how do they compare? Marathon Petroleum Corp trades at $319.23 (market cap $92.05B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Marathon Petroleum Corp is far larger — about 8.2× BIO-TECHNE Corp's market cap, and Marathon Petroleum Corp pays the higher dividend (1.24%). Which is the better fit depends on your goals.
| MPC | TECH | |
|---|---|---|
Market Cap | $92.05B | $11.16B |
Sector | Energy | Health |
52-Week High | $315.31 | $72.12 |
52-Week Low | $158.59 | $43.31 |
Enterprise Value | $124.23B | $11.24B |
Dividend Yield | 1.24% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $319.76, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a 27.92% ROE and 3.42% net margin, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus remains strongly bullish with 25 buy ratings and a $292.70 price target. The company benefits from strong refining margins and strategic upgrades driving profitability.
MPC presents a compelling investment case with strong profitability metrics and positive analyst sentiment, though investors should monitor declining revenue trends and elevated debt levels. The stock's current price near resistance levels suggests potential for consolidation, while refining margin advantages and limited Russian capacity create tailwinds. Key risks include oil price volatility and macroeconomic pressures on energy demand.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
